🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank

    BRIGHT MINDS BIOSCIENCES INC.

    Previously Treated Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  2. Drug: B10 L-BPA Injection

    Heron Therapeutics

    Head and Neck Cancer

    phase 2 small molecule active

    1 trial

  3. Drug: GC4419

    Galera Therapeutics

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  4. Dupilumab

    Regeneron UK Limited

    Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  5. Dupilumab

    Coherus Oncology

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  6. Durvalumab + Oleclumab

    MedImmune

    Stage III Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  7. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    Cervical Cancer

    phase 2 mab active

    1 trial

  8. E7386, Doxorubicin EBEWE 2 mg/ml koncentratas infuziniam tirpalui, E7386, Паклитаксел Ебеве 6 mg/ml концентрат за инфузионен разтвор, Paclitaxel Aurobindo 6 mg/ml concentrato per soluzione per infusione, Doxorubicina Aurobindo 2 mg/ml concentrato per soluzione per infusione, LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules

    Eisai Co.,

    Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor

    phase 2 small molecule active

    1 trial

  9. EG-70 (phase 1)

    Shanghai Antengene Corporation Limited

    Superficial Bladder Cancer

    phase 2 small molecule active

    1 trial

  10. EGF816, EGF816, LEE011, LEE011

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 2 small molecule active

    1 trial

  11. EGFR-TK Inhibitor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nonsmall Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. ELIGARD 22,5 mg, poudre et solvant pour solution injectable

    The George Institute

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

  13. ENCORAFENIB , CETUXIMAB

    The George Institute

    Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.

    phase 2 small molecule active

    1 trial

  14. ENMD-2076

    CASI Pharmaceuticals

    Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  15. ENMD-2076

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  16. EOF5

    Fudan University

    Gastric Cancer

    phase 2 small molecule completed

    1 trial

  17. EP0062, ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  18. EPI-7386, Xtandi - 40 mg soft capsules

    Lacuna Pharma Pty Ltd

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  19. EXEMESTANE, ANASTROZOLE, LETROZOLE

    Ningbo Cancer Hospital

    Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse

    phase 2 small molecule active

    1 trial

  20. EXEMESTANE, ANASTROZOLE, LETROZOLE, TAMOXIFEN

    Ningbo Cancer Hospital

    Postmenopausal patients with small (pT1a-b pN0) hormone receptor positive (HR⁺) and HER2 negative (HER2⁻) early breast cancer with a Luminal A phenotype and at low risk of recurrence.

    phase 2 small molecule active

    1 trial

  21. Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

    The George Institute

    Metastatic pancreatic adenocarcinoma

    phase 2 other active

    1 trial

  22. Elacestrant

    Context Therapeutics

    Breast Cancer

    phase 2 small molecule terminated

    2 trials

  23. Elironrasib

    Revolution Medicines

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  24. Encorafenib, Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules, Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules

    Pfizer Australia Pty Ltd

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources